Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)

NAEnrolling by invitationINTERVENTIONAL
Enrollment

14,000

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cervical Intraepithelial Neoplasia Grade 2/3Adenocarcinoma in Situ
Interventions
OTHER

Frequent information of cytological/ HPV DNA screening results

"All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end."

Trial Locations (18)

15110

Nuorisotutkimusasema, PSHP/ Tampereen yliopisto, Lahti

26100

Nuorisotutkimusasema, PSHP; Tampereen yliopisto, Rauma

28100

HPV-tutkimukset, Pori

33100

Nuorisotutkimusasema; PSHP/ Tamereen yliopisto, Tampere

38200

HPV-tutkimukset, Sastamala

40100

HPV-tutkimukset, Hämeenlinna

HPV-tutkimukset, Jyväskylä

45100

HPV-tutkimukset, Kouvola

48100

Nuorisotutkimusasema, PSHP/Tampereen yliopisto, Kotka

60100

HPV-tutkimukset, Seinäjoki

70100

Nuorisotutkimusasema, PSHP; Tampereen yliopisto, Kuopio

74100

HPV-tutkimukset, Iisalmi

78300

HPV-tutkimukset, Varkaus

80100

HPV-tutkimukset, Joensuu

90100

HPV-tutkimukset, Oulu

94100

Nuorisotutkimusasema, PSHP/ Tampereen yliopisto, Kemi

Unknown

HUS, Helsinki

06100

HPV-tutkimukset, Porvoo

All Listed Sponsors
collaborator

Tampere University

OTHER

collaborator

European Union

OTHER

collaborator

Karolinska Institutet

OTHER

lead

Tampere University Hospital

OTHER